Table 1.
Drug targets and genetic polymorphisms.
| Gene-target ID | Gene | Active Compounds | Drug development stage | SNP (non-synonymous) | Non-reference allele frequency >5% (non-synonymous) | Known antimalarial resistant mutations |
|---|---|---|---|---|---|---|
| PfcPheRs (PF3D7_0109800) | Phenylalanine-tRNA ligase alpha subunit | Bicyclic azetidine | Nonclinical development | 44 (28) | 5 (3) | L550V |
| Pfcarl (PF3D7_0321900) | Cyclic amine resistance locus protein | Imidazolopiperazines, benzimidazolyl piperidines | Clinical trials | 152 (90) | 34 (21) | 0 |
| Pfpi4k (PF3D7_0509800) | Phosphatidylinositol-4 kinase | Imidazopyrazines, aminopyridine class, quinoxaline, 2-aminopyradines | Clinical trials | 182 (129) | 62 (49) | 0 |
| Pfdhodh (PF3D7_0603300) | Ddihydroorotate dehydrogenase | triazolopyrimidine-based inhibitor, N-alkyl-5-thiophene-2-carboxamides | Clinical trials | 50 (26) | 8 (3) | 0 |
| Pfact (PF3D7_1036800) | Acetyl-CoA transporter | Imidazolopiperazines | Clinical trials | 46 (22) | 13 (6) | 0 |
| Pfugt (PF3D7_1113300) | UDP-galactose transporter | Imidazolopiperazines | Clinical trials | 30 (12) | 10 (6) | 0 |
| Pfatp4 (PF3D7_1211900) | P-type cation transporting ATPase | Spiroindolones, sulfonamide, carboxamide, pyrazoles,dihydroisoquinolones | Clinical trials | 123 (75) | 34 (23) | 0 |
| Pfprs (PF3D7_1213800) | Proline-tRNA synthetase | Febrifugine and derivates | Nonclinical development | 66 (31) | 16 (9) | 0 |
| Pfrab11A (PF3D7_1320600) | Ras-related protein Rab-11A | Aminopyridine class | Clinical trials | 5 (1) | 0 (0) | 0 |
| PfeEF2 (PF3D7_1451100) | Elongation factor 2 | Quinoline-4-carboxamide (DDD107498) | Preclinical development | 34 (1) | 4 (0) | 0 |
| PfCYTB (mal_mito_3) | Cytocrome b | Atovaquone, tetracyclic benzothiazepine, benzylsulfonamide, decoquinate | Clinical drug, clinical trial | 46 (9) | 7 (2) | 0 |